Verenium Announces Commercial Launch Of Pyrolase® HT Product

         Verenium Announces Commercial Launch Of Pyrolase® HT Product

--High-performance, eco-friendly next-generation enzyme now available for the
oil and gas industry--

--Verenium to exhibit at the Society of Petroleum Engineers Hydraulic
Fracturing Technology Conference February 4th - 6th--

PR Newswire

SAN DIEGO, Feb. 4, 2013

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a
leading industrial biotechnology company focused on the development and
commercialization of high-performance enzymes, today announced the commercial
launch of Pyrolase^® HT cellulase, a next-generation cellulase enzyme for use
as a biocatalyst to break down the guar-based gel used in hydraulic


Pyrolase^® HT is a highly thermo-stable enzyme developed by Verenium
scientists using proprietary DirectEvolution^® technology to meet more
demanding performance requirements and expand the addressable market that can
be serviced by its product line.

In July 2012, Verenium announced that the Company had received regulatory
authorization from the Environmental Protection Agency (EPA) to market
Pyrolase^® HT cellulase. In laboratory evaluations conducted by several
oilfield service companies, it has demonstrated that it functions well in more
extreme temperature ranges and higher pH conditions.

"We are pleased to announce the commercial availability of Pyrolase^® HT which
expands our product offering to the oilfield services industry," said James
Levine, President and Chief Executive Officer. "As we have stated before,
Pyrolase^® HT provides several important economic, operational and
environmental advantages over the traditional chemical breakers currently
used, both during the fracturing process and over the remaining operational
life of the well."

Verenium estimates the addressable market in the U.S. for guar breakers in
hydraulic fracturing is up to $250 million, of which currently marketed enzyme
products address approximately 10% or $25 million. The Company believes
Pyrolase^® HT represents an advancement in performance properties that can
expand the share of this market addressable by enzymes beyond the current
estimated ten percent.

"This is a market where we see significant opportunity to drive further
adoption of enzyme solutions and to further grow and diversify our revenue
base," added Levine.

Additional Information about Pyrolase^® HT Cellulase

Verenium co-authored a scientific paper based on research conducted with this
high-performance enzyme for breaking cross-linked fracturing fluids under
extreme downhole conditions. The findings, A Superior High-performance Enzyme
for Breaking Borate Cross-linked Fracturing Fluids under Extreme Well
Conditions, was presented during the Fluids Optimization Technical Session at
the Society of Petroleum Engineers (SPE) Annual Technical Conference in
October 2012.

Upcoming Exhibition

Verenium is scheduled to exhibit at the Society of Petroleum Engineers (SPE)
Hydraulic Fracturing Technology Conference (booth #423) February 4 - 6, 2013
at the Woodlands Waterway Marriot Hotel and Convention Center in The
Woodlands, Texas. For more information on the SPE Hydraulic Fracturing
Technology Conference visit

About Verenium

Verenium, an industrial biotechnology company, is a global leader in
developing high-performance enzymes. Verenium's tailored enzymes are
environmentally friendly, making products and processes greener and more
cost-effective for industries, including the global food and fuel markets.

Forward-Looking Statements

Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include, but are not limited to, statements related to Verenium's ability to
commercialize its products, enhance its manufacturing capabilities, capture
near-term and longer-term growth and prospects, and reach profitability. Such
statements are only predictions, and actual events or results may differ
materially from those projected in such forward-looking statements. Factors
that could cause or contribute to the differences include, but are not limited
to, risks associated with Verenium's strategic focus, technologies, products
and product candidates and product pipeline (including Verenium's ability to
identify, develop and commercialize new products and product candidates,
either independently or with collaborators or partners, and market demand for
those products and product candidates), dependence on patents and proprietary
rights, protection and enforcement of its patents and proprietary rights, the
commercial prospects of the industries in which Verenium operates and sells
products, Verenium's dependence on manufacturing and/or license
agreements,its ability to achieve milestones under existing and future
collaboration agreements, the ability of Verenium and its partners to
commercialize its technologies and products (including by obtaining any
required regulatory approvals) using Verenium's technologies, the timing for
launching any commercial products and projects, the ability of Verenium and
its collaborators to market and sell any products that it or they
commercialize, the development or availability of competitive products or
technologies, the future ability of Verenium to enter into and/or maintain
collaboration and joint venture or partnership agreements and licenses on a
timely basis or at all, and risks and other uncertainties more fully described
in Verenium's filings with the Securities and Exchange Commission, including,
but not limited to, Verenium's annual report on Form 10-K for the year ended
December 31, 2011 and any updates contained in its subsequently filed
quarterly reports on Form 10-Q. These forward-looking statements speak only
as of the date hereof, and Verenium expressly disclaims any intent or
obligation to update these forward-looking statements.


Sarah Carmody

Sr. Corporate Communications Manager


SOURCE Verenium Corporation

Press spacebar to pause and continue. Press esc to stop.